Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALFAN vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum and Plasmodium vivax (including chloroquine-resistant strains)
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
Adults: 500 mg orally once daily.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Halofantrine is extensively metabolized in the liver, primarily via cytochrome P450 (CYP) 3A4, to its active metabolite N-desbutylhalofantrine. Both parent drug and metabolite are highly bound to plasma proteins.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
25-30% bound to serum albumin.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
0.9-1.0 L/kg, indicating distribution into total body water.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: 88-95%; rectal: 80-90%; intramuscular: 96%.
Oral: 80-90%.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 125 mg once daily.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: not recommended.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
10 mg/kg orally once daily; maximum 500 mg/day.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
No specific adjustment; monitor renal function due to age-related decline.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
Cardiotoxicity: HALFAN prolongs the QT interval and can cause serious, life-threatening ventricular arrhythmias (e.g., torsade de pointes). Do not use in patients with pre-existing QTc prolongation, electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), or those taking other drugs that prolong the QT interval. ECG monitoring is required before, during, and after therapy.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Cardiotoxicity: QTc interval prolongation; contraindicated in patients with conduction disorders or concurrent QT-prolonging drugs.,Hematologic: May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.,Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.,Hepatic: Use with caution in hepatic impairment.,Pregnancy: Not recommended (teratogenic in animal studies).,Drug interactions: Avoid with CYP3A4 inhibitors and QT-prolonging agents.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
Pre-existing QTc prolongation or congenital long QT syndrome,History of ventricular arrhythmias,Hypokalemia or hypomagnesemia,Concurrent use of drugs that prolong the QT interval (e.g., class IA/III antiarrhythmics, some antibiotics, antipsychotics),G6PD deficiency (relative),Pregnancy and breastfeeding (contraindicated in pregnancy)
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Take with a high-fat meal (e.g., full yogurt, burger, nuts) to increase absorption by up to 10-fold. Grapefruit juice may increase halofantrine levels; avoid concurrent use. Avoid alcohol due to additive QT-prolonging effects.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and third trimesters: Limited data; risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
HALFAN is excreted in human milk. M/P ratio not reported. Due to potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No specific dosing adjustments recommended in pregnancy. Monitor for increased clearance and consider dose titration based on clinical response and side effects. Use lowest effective dose.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Halofantrine (Halfan) is reserved for chloroquine-resistant Plasmodium falciparum malaria due to risk of fatal cardiotoxicity (QT prolongation, ventricular arrhythmias). Must obtain baseline ECG and monitor QTc; contraindicated if QTc >450 ms, family history of sudden death, or concurrent use of other QT-prolonging drugs. Administer with fatty food to enhance absorption, but food content may increase risk of arrhythmias. Do not repeat therapy within 6 weeks due to cumulative toxicity.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take with a full meal high in fat to improve absorption.,Complete the full course even if symptoms improve.,Report immediately any chest pain, palpitations, fainting, or irregular heartbeat.,Avoid use with certain anti-malarials (e.g., quinine, mefloquine) and other drugs that affect heart rhythm.,Inform doctor if you have a personal or family history of heart problems, fainting, or electrolyte disturbances.,Do not use during pregnancy or breastfeeding unless specifically directed.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALFAN vs ARALEN, answered by our medical review team.
HALFAN is a Antimalarial that works by HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALFAN and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALFAN is: Adults: 500 mg orally once daily.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALFAN and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALFAN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and thi. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.